Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Medical Industry Today.
Press releases published on June 15, 2025
Mindworks NLP Offers a Smoking Cessation Group Hypnosis Live Event in Bellevue – June 21
EIN Presswire
·
June 15, 2025
Mindworks NLP announces a public group hypnosis seminar on June 21 to help participants quit smoking using powerful subconscious change techniques. BELLEVUE, WA, UNITED STATES, June 15, 2025 /EINPresswire.com/ -- In a time when public health and …
Redefining Fabry Disease Care: Gene Therapy and Long-Acting ERT Prepare to Disrupt Status Quo | Competitive Intellignece
EIN Presswire
·
June 15, 2025
Fabry disease treatment is advancing rapidly with gene therapies and next-gen ERTs promising durable efficacy, reduced burden, and broader mutation coverage. AUSTIN, TX, UNITED STATES, June 15, 2025 /EINPresswire.com/ -- Fabry Disease, a rare, X-linked …
Rewriting the Playbook in MPS I: CNS-Penetrant ERTs and Gene Therapies Usher in a New Treatment Era | CI Insights
EIN Presswire
·
June 15, 2025
Emerging CNS‑targeting ERTs and gene therapies for MPS I show promise for neurocognitive benefits, reduced treatment burden, and better outcomes. AUSTIN, TX, UNITED STATES, June 15, 2025 /EINPresswire.com/ -- Mucopolysaccharidosis type I (MPS I) is an …
Hunter Syndrome Therapeutics Evolve: Novel CNS-Targeting Therapies Set to Challenge Elaprase’s Market Monopoly
EIN Presswire
·
June 15, 2025
New CNS-penetrant therapies and gene therapies are poised to transform the Hunter Syndrome landscape, ending Elaprase’s long-standing treatment dominance. AUSTIN, TX, UNITED STATES, June 15, 2025 /EINPresswire.com/ -- Hunter Syndrome ( …
Thorncrest Dental Brings Advanced Laser Dentistry to Etobicoke with Picasso Soft Tissue Laser
EIN Presswire
·
June 15, 2025
ETOBICOKE, ONTARIO, CANADA, June 15, 2025 /EINPresswire.com/ -- Thorncrest Dental is proud to introduce the Picasso Soft Tissue Laser, a cutting-edge addition to its suite of dental technologies, now available to patients in the Etobicoke community. This …
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
GlobeNewswire
·
June 15, 2025
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent …
Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …
GlobeNewswire
·
June 15, 2025
EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe …
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
GlobeNewswire
·
June 15, 2025
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp …
Tom Jackobs Offers Fractional Sales Management for Heart-Led Wellness Practices
EIN Presswire
·
June 15, 2025
New service helps mission-driven businesses improve sales performance without building a full in-house sales team. LOS ANGELES, CA, UNITED STATES, June 15, 2025 /EINPresswire.com/ -- Tom Jackobs, international sales strategist, is now offering …
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
GlobeNewswire
·
June 15, 2025
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, …
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
GlobeNewswire
·
June 15, 2025
– Pharmacology modeling data presented at the European Academy of Allergy …
D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth
GlobeNewswire
·
June 15, 2025
Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle- …